Opioid Doc Sentenced; World's First Sickle Cell Gene Tx; FTC Warns Diet Influencers Health news and commentary from around the Web gathered by staff Nov 17, 2023
FDA Panel: Tolerating Approval Outliers Would Set 'Dangerous Precedent' No easy answers for two drugs for rare lymphoma on long cruise with accelerated approval Nov 16, 2023
ASTRO Updates Guidelines on Partial Breast Irradiation for Early Invasive Cancer Evidence from RCTs indicates "oncologic equivalence" between partial and whole-breast irradiation Nov 16, 2023
FDA OKs New Option for Advanced ROS1-Positive Lung Cancer Drug achieved high response rates in TKI-naive and TKI-pretreated patients Nov 16, 2023
'We're Not There Yet': CAR T-Cell Therapy for Renal Cell Carcinoma Potential standard of care after current therapies, but key obstacles remain in the way Nov 15, 2023
FDA OKs Product to Thwart Bloodstream Infections During Dialysis Taurolidine-heparin solution reduced infections by 71% versus heparin alone Nov 15, 2023
Targeting New Pathways to Improve Outcomes in Renal Cell Carcinoma Building on recent success requires intervention at multiple steps in the cancer immunity cycle Nov 14, 2023
Lymphoma Drug Copanlisib to Be Pulled From U.S. Market Failed confirmatory trial takes down another PI3K inhibitor Nov 14, 2023
Diabetes Linked to Higher Colorectal Cancer Risk Associated risks highest in those with recent diagnoses Nov 14, 2023
No Boost in Outcomes for Clear Cell RCC With Higher Belzutifan Dose A quarter of patients responded whether at the recommended or higher dose Nov 13, 2023
Pancreatic Cancer Doesn't Have to Be a Death Sentence Early detection is the key to increasing survival rates Nov 13, 2023
Tyrosine Kinase Inhibitor Active in Heavily Treated Renal Cell Carcinoma Responses to "special drug" zanzalintinib in cabozantinib-exposed and unexposed patients Nov 11, 2023
Zoonotic Spillovers; DNA and RNA Testing for Cancer Risk Also in TTHealthWatch: genes and health conditions among Icelanders Nov 11, 2023 podcast
First Treatment Approved for Genetic Clotting Disorder Adzynma indicated as prophylactic or on-demand enzyme replacement therapy in cTTP Nov 10, 2023
Vitamin D for Neuropathy; Good & Bad News for CAR-T; New Labeling for Surgical Mesh News, features, and commentary about cancer-related issues Nov 10, 2023
Bispecific Antibody Shows Clinical Activity in Recurrent Ovarian Cancer Alone or combined with a PD-1 inhibitor, ubamatamab showed promise in phase I trial Nov 09, 2023
Moving Beyond the 'Angelina Jolie Effect' to Address Cancer Disparities A "local heroes effect" can better reach communities of color Nov 09, 2023
New Oral Drug Approved for Metastatic Colorectal Cancer In phase III trials of pretreated patients, fruquintinib improved survival versus placebo Nov 09, 2023
Novel Therapies Show Early Promise in Advanced Gastroesophageal Cancers Results look good, but more data needed Nov 08, 2023
Senate Confirms Monica Bertagnolli as Next NIH Director Vote was 62-36 in favor of the current National Cancer Institute director Nov 07, 2023
FDA Panel Backs High-Risk Designation for Salvaged Blood Irradiators With Class III designation, sponsors would have to prove safety, efficacy with randomized trials Nov 07, 2023
T-DXd Tied to Encouraging Survival in HER2-Expressing Gyn Cancers More responses, longer OS in subset with the highest levels of HER2 expression Nov 07, 2023
Sexual Health Suffered After Radical Hysterectomy for Early Cervical Cancer Compared with simple hysterectomy, analysis shows more sexual toxicities, worse quality of life Nov 07, 2023
Lung Cancer Survival High at 20 Years With Screen-Detected Tumors After two decades, lung cancer-specific survival remained at 81% in I-ELCAP program Nov 07, 2023
Mixed Results for Tiragolumab/Atezolizumab Combo in PD-L1+ Recurrent Cervical Cancer Overall response beats historical benchmark, but misses significance target Nov 06, 2023
RAF/MEK and FAK Inhibitor Combo Effective in Low-Grade Serous Ovarian Cancer Impressive overall response rate with avutometinib-defactinib in RAMP 201 trial Nov 05, 2023
Maintenance Selinexor May Boost PFS in TP53 Wild-Type Advanced Endometrial Cancer Particularly strong PFS signal seen in patients that were mismatch repair proficient Nov 05, 2023
Adding Atezolizumab Improves Survival in Advanced Cervical Cancer Trial confirms the role of first-line checkpoint inhibition in metastatic or recurrent disease Nov 03, 2023
Evidence of Safety, Efficacy for Salvaged Blood Irradiators Lacking, FDA Staff Say Devices are aimed at preventing metastasis during surgery Nov 03, 2023
Wearables as Cancer Monitors; No China Price Break; Cancer Mystery in Appalachia News, features, and commentary about cancer-related issues Nov 03, 2023
Transitioning Cancer Survivors Away From Oncologic Care It's time for a new model of care Nov 03, 2023
False-Positive Mammograms May Indicate Higher Breast Cancer Risk in the Future Swedish cohort study shows a 61% increased risk over 20 years Nov 02, 2023
Years of Progressing Facial Numbness and Deteriorating Vision Drives Diagnosis Suspect perineural recurrence of cutaneous squamous cell carcinoma, experts urge Nov 02, 2023
Lambert-Eaton Myasthenic Syndrome Underdiagnosed Alongside SCLC in the U.S. Findings suggest patients with SCLC are not screened for LEMS, despite their association Nov 02, 2023
ACS: Millions More Should Get Lung Cancer Screening Notably, new recommendations say it doesn't matter when a person quit smoking Nov 01, 2023
Reduced-Dose Schedule of Cabazitaxel Viable for Seniors With mCRPC Grade 3 or higher neutropenia, neutropenic complications reduced by 12-fold Nov 01, 2023
Potential Cure for Sickle Cell Clears Hurdle for Approval FDA advisors suggest the benefits of gene therapy outweigh risks of off-target editing Oct 31, 2023
Personalized Intervention Helps CRC Screening Decisions for Older Adults Patients receiving intervention were less likely to undergo screening if benefits were low Oct 31, 2023
The Exciting Potential of Antibody-Drug Conjugates in Lung Cancer Roy Herbst, MD, PhD, leads a discussion on ADCs targeting TROP2, HER2, and HER3 Oct 30, 2023 video
FDA Reviewers Question Safety of Sickle Cell Gene Therapy Efficacy results "strongly positive," but unintended off-target effects a question Oct 30, 2023
